Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03628235 · ClinicalTrials.gov registry record
HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States
A clinical trial, sponsored by CHDI Foundation.
- Completed
- Registry status
- 233
- Enrollment target
NCT03628235: Completed study, sponsored by CHDI Foundation.
NCT03628235 is a clinical trial that has completed, run by CHDI Foundation. The registered enrollment target is 233 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03628235 has completed, sponsored by CHDI Foundation.
- COMPLETED
- Registry status
- 233 participants
- Enrollment target
Study Summary
Huntington's disease (HD) is a rare, inherited and progressive neurodegenerative disorder for which hallmark symptoms include movement disorders, loss of cognitive faculties and psychiatric disturbances. With the progression of the disease, patients require increasing level of medical care, caregiver support, and long-term care, which lead to substantial burden of illness. Very little data are available on the direct or indirect costs for HD. The direct medical costs of HD in the US have been summarized from retrospective commercial and Medicaid claims data analysis. The indirect and out-of-pocket costs of HD in the US have not been quantified. This study will help to bridge these gaps. This study is a single-assessment, cross-sectional online survey administered to Huntington disease gene expansion carriers (HDGECs) and companions of HDGECs by HD stage to understand the indirect and out-of-pocket costs of Huntington's disease in the US.
Primary Outcome
Productivity loss is measured by annual lost wages and it is collected in the survey's employment questionnaires and WPAI
Interventions
- BEHAVIORAL Online survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2020-06-21 |
| Est. Completion | 2022-06-21 |
What the finished NCT03628235 record still lists
NCT03628235 is an observational study that tracks outcomes without assigning an intervention. The registered 233 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Online survey is the first listed.
NCT03628235 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03628235 about?
NCT03628235 is a clinical study titled "HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States". Huntington's disease (HD) is a rare, inherited and progressive neurodegenerative disorder for which hallmark symptoms include movement disorders, loss of cognitive faculties and psychiatric disturbances. With the progression of the disease, patients require increasing level of medical care, caregive...
What is the current status of trial NCT03628235?
This trial is currently completed. The enrollment target is 233 participants. The study started on 2020-06-21. Estimated completion is 2022-06-21.
What interventions are being tested in trial NCT03628235?
The interventions under investigation include: Online survey (BEHAVIORAL).
Who is sponsoring clinical trial NCT03628235?
This trial is sponsored by CHDI Foundation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06993844 · 233 participants · Phase 1
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- NCT07141706 · 233 participants · Phase 1
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI